Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
April 18, 2014, 05:42:05 PM

Login with username, password and session length


Members
  • Total Members: 22214
  • Latest: chuff
Stats
  • Total Posts: 620274
  • Total Topics: 46731
  • Online Today: 254
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: MVA-BNŽ polytope against HIV  (Read 1886 times)

0 Members and 1 Guest are viewing this topic.

Offline MitchMiller

  • Member
  • Posts: 453
MVA-BNŽ polytope against HIV
« on: October 25, 2006, 10:23:39 PM »
Bavarian Nordic A/S announced today that the company has initiated a Phase I and a Phase I/II clinical study in Europe with MVA-BNŽ polytope vaccine against HIV. The vaccine was recently released from the company’s facility in Berlin for use in clinical trials. The purpose of these studies is to evaluate the safety and immunogenicity of the vaccine in healthy and HIV-infected subjects. Results from both studies are expected in the second half of 2007.

MVA-BNŽ polytope is the second of the company’s three vaccine candidates to enter clinical trials. It is being developed as both a prophylactic and therapeutic vaccine, and thus is more advanced than MVA nef, which is being developed by Bavarian Nordic as a therapeutic vaccine only.

The MVA-BNŽ polytope vaccine only encodes for small regions of the HIV proteins that have been shown to stimulate a strong T-cell response in people infected with HIV. As such, this vaccine has been designed to generate a broad immune response to many of the HIV proteins, making this a potent vaccine strategy to fight against HIV.

Bavarian Nordic is currently preparing the filing of an Investigational New Drug Application (IND) with the Food and Drug Administration (FDA). Under this IND two additional Phase II studies with MVA-BNŽ polytope are expected to start in the US in the first half of 2007. Both studies will be funded by the National Institutes of Health (NIH).

According to the WHO, approximately 40 million people are living with HIV, of which almost 3 million people die every year from AIDS-related complications. It is estimated that around 4 million people are infected with HIV every year. More than 95% of all new infections occur in developing countries, making HIV among the most serious threat not only to global health, but to global development.



Offline J220

  • Member
  • Posts: 587
Re: MVA-BNŽ polytope against HIV
« Reply #1 on: October 26, 2006, 01:56:44 AM »
Everyt time I hear news like this it brightness my day...wheels are in motion...! Thanks for posting that Mitch.
"Hope is my philosophy
Just needs days in which to be
Love of Life means hope for me
Born on a New Day" - John David

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.